Major Breakthrough: Xinda Biotechnology's Nylotinib Included in NCCN Guidelines for Chronic Myeloid Leukemia Treatment

In a significant development, Xinda Biotechnology's groundbreaking drug, Nylotinib, has been recognized by the international oncology community once again. The latest edition of the National Comprehensive Cancer Network (NCCN) guidelines for Chronic Myeloid Leukemia (CML) treatment in the United States has officially included Nylotinib, marking a major milestone in its global recognition. This article delves into the implications of this achievement and highlights the efficacy and safety of Nylotinib in CML patients.

Nylotinib, marketed as "Nylotinib®," is classified as a first-class new drug in China and is celebrated as a "Best-in-class" medication worldwide. It is the first and only approved third-generation BCR-ABL inhibitor in China, exhibiting remarkable effectiveness against various BCR-ABL mutations, including the T315I mutation. The drug has demonstrated outstanding results in clinical studies, prompting its inclusion in the NCCN guidelines.

The NCCN, a non-profit academic organization comprising leading cancer centers in the United States, regularly updates and publishes cancer treatment guidelines that have become the gold standard for clinical decision-making in the field of oncology. By referencing the efficacy data from Phase I and Phase II clinical trials conducted in China, the NCCN guidelines have acknowledged Nylotinib's positive impact on CML patients.

Among CML patients in the chronic phase (CP) and accelerated phase (AP), Nylotinib exhibited a significant major cytogenetic response rate (MCyR) of 79% and 47%, respectively. The complete cytogenetic response rate (CCyR) was 69% and 47%, while the major molecular response rate (MMR) stood at 56% and 45%. Importantly, Nylotinib demonstrated a favorable safety profile, with manageable adverse events mostly graded as 1-2, including platelet reduction, elevated triglyceride levels, and mild increases in liver enzymes such as creatine kinase and alanine aminotransferase. Notably, Nylotinib showed minimal occurrence or rare instances of arterial occlusion and other dose-related adverse reactions commonly associated with tyrosine kinase inhibitors (TKIs) during treatment.

Furthermore, clinical data presented at the 2023 American Society of Hematology (ASH) annual meeting showcased Nylotinib's excellent tolerability and efficacy in CML patients who had received deep TKI therapy and those with the T315I mutation. Comparative studies against the Best Available Therapy (BAT), including imatinib, dasatinib, and nilotinib, demonstrated that Nylotinib significantly prolonged event-free survival (EFS) and reduced the risk of events by 60%. Additionally, Nylotinib exhibited notable therapeutic potential in patients who had failed treatment with third-generation TKI ponatinib or the mutant-specific inhibitor asciminib.

The inclusion of Xinda Biotechnology's Nylotinib in the latest NCCN guidelines for CML treatment marks a major breakthrough and testament to its international recognition as a "Best-in-class" drug. The drug's exceptional efficacy, safety, and tolerability profile, along with its ability to target various BCR-ABL mutations, including the T315I mutation, have positioned Nylotinib as a promising therapeutic option for CML patients worldwide. The approval and commercialization of Nylotinib underscore the continuous efforts to advance cancer treatment and improve patient outcomes in the field of oncology.